SEC Form 4 · accession 0000899243-18-000485
ALPINE IMMUNE SCIENCES, INC. · ALPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanford L Peng
Officer — See Remarks
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626199
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1,F2 | $11.31 | Jan 2, 2018 | A | 65,000 | A | — | Jan 1, 2028 | Common Stock | 65,000 | 65,000 | D |
Explanation of responses
- F1The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
- F21/4th of the shares subject to the option become vested and exercisable on January 2, 2019 and 1/36th of the remaining shares subject to the option shall vest monthly thereafter.
Remarks
Exec VP of Research and Development and CMO